PLUS THERAPEUTICS, INC. Logo

PLUS THERAPEUTICS, INC.

Develops targeted radiotherapeutics for difficult-to-treat cancers in adults and children.

PSTV | US

Overview

Corporate Details

ISIN(s):
US23283K2042 (+1 more)
LEI:
Country:
United States of America
Address:
4200 MARATHON BLVD., 78756 AUSTIN

Description

Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company's technology platform is designed to deliver high-dose, localized radiation directly to tumors. Its core approach involves encapsulating Rhenium radioisotopes (186Re and 188Re) within nanoliposomes. The lead investigational drug, REYOBIQ™ (rhenium Re186 obisbemeda), is a nanoliposome therapy targeting brain and central nervous system (CNS) cancers, including recurrent glioblastoma and leptomeningeal metastases. A second pipeline program, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is a radioembolization therapy being developed for solid organ cancers, such as liver cancer. The use of Rhenium allows for both therapeutic beta radiation and gamma imaging during treatment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-17 08:35
8-K
English ZIP 65.6 KB
2025-11-05 09:30
4
English ZIP 7.1 KB
2025-10-30 17:20
10-Q
English ZIP 1.8 MB
2025-10-30 17:15
8-K
English ZIP 113.6 KB
2025-10-21 09:25
8-K
English ZIP 663.7 KB
2025-10-03 18:30
4
English ZIP 7.4 KB
2025-10-03 18:30
4/A
English ZIP 7.8 KB
2025-10-03 18:30
4
English ZIP 7.3 KB
2025-10-03 18:30
4/A
English ZIP 7.7 KB
2025-08-26 08:30
8-K
English ZIP 56.4 KB
2025-08-25 09:30
4
English ZIP 6.7 KB
2025-08-22 19:25
S-8
English ZIP 97.9 KB
2025-08-15 18:29
4
English ZIP 7.4 KB
2025-08-15 18:29
4
English ZIP 7.5 KB
2025-08-15 18:29
4
English ZIP 7.3 KB

Automate Your Workflow. Get a real-time feed of all PLUS THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PLUS THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PLUS THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alzinova AB Logo
Clinical-stage biopharma developing immunotherapies for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops and commercializes therapeutics to improve cardiovascular health.
United States of America
AMRN
AMGEN INC Logo
A biotechnology company developing human therapeutics for serious illnesses.
United States of America
AMGN
Industrial biotechnology company specializing in specialty enzymes and proteins.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Biotechnology company developing therapies for rare genetic and devastating diseases.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Specialty manufacturer of high-purity chiral amino acids and their derivatives.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops, manufactures, and distributes generic and specialty pharmaceuticals.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops, manufactures, and markets technically challenging medications.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Develops therapies for neurodegenerative diseases and other unmet medical needs.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Biopharmaceutical firm developing boron-based drugs for infectious diseases.
United States of America
ANTX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.